Immunoassay Disruption by High-Dose Biotin Therapy: Fair Warning for Neonatal Care Physicians

Charles R Lefevre (1) , Lucas Peltier (2) , Léna Damaj (2) , Jessica Valaize (2) , Claude Bendavid (3) , Caroline Moreau (2, 3)

1 Irset - Institut de recherche en santé, environnement et travail
2 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
3 NuMeCan - Nutrition, Métabolismes et Cancer

Very-high-dose biotin therapy is sometimes prescribed in newborns with pharmacoresistant neonatal epileptic encephalopathy or with suspicion of inherited metabolic disorders such as biotinidase deficiency, holocarboxylase synthetase deficiency, or Leigh syndrome (in biotin-thiamine-responsive basal ganglia disease due to SLC19A3 mutation).1,2 Regardless of the child’s weight (2-10 kg), tremendous doses of biotin are administrated (10-300 mg/day, e.g., 3-100 mg/kg/day for a 3-kg newborn).

Mots clés: Analytical interference; Biotin; Immunoassay; Neonatal epileptic encephalopathy

Domaines: Sciences du Vivant [q-bio]; Pédiatrie

Charles R Lefevre, Lucas Peltier, Léna Damaj, Jessica Valaize, Claude Bendavid, et al.. Immunoassay Disruption by High-Dose Biotin Therapy: Fair Warning for Neonatal Care Physicians. Pediatric Neurology, 2020, 112, pp.8-9. ⟨10.1016/j.pediatrneurol.2020.07.007⟩. ⟨hal-02930037⟩